Crutchfield Bradford's Form 4 filing
10x Genomics, Inc. (TXG) · filed Nov 16, 2021
- Accession no.
- 0001567619-21-020599
- Filed
- Nov 16, 2021
- Trade date
- Nov 12, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.80M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crutchfield BradfordCIK 0001246406 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | Class A Common Stock | MOption exerciseAcquired | +17,000 | $1.16 | +$19,720 | 60,336 | Direct | |
| Nov 12, 2021 | Class A Common Stock | SSaleDisposed | −1,030 | $163.10F2 | −$167,993 | 59,306 | Direct | |
| Nov 12, 2021 | Class A Common Stock | SSaleDisposed | −4,122 | $164.18F3 | −$676,749.96 | 55,184 | Direct | |
| Nov 12, 2021 | Class A Common Stock | SSaleDisposed | −6,872 | $164.87F4 | −$1,132,986.64 | 48,312 | Direct | |
| Nov 12, 2021 | Class A Common Stock | SSaleDisposed | −4,776 | $165.89F5 | −$792,290.64 | 43,536 | Direct | |
| Nov 12, 2021 | Class A Common Stock | SSaleDisposed | −100 | $167.27 | −$16,727 | 43,436 | Direct | |
| Nov 12, 2021 | Class A Common Stock | SSaleDisposed | −100 | $168.34 | −$16,834 | 43,336 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | Class A Common Stock | MOption exerciseDisposed | −17,000 | $0.00 | $0 | 443,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $162.49 to $163.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $163.50 to $164.495. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $164.50 to $165.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $165.51 to $166.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.